Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive News
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Submitted by Jeffrey Neal Johnson. Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.
And right now, you can claim a stake before the company goes public, starting with just $500.
Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. Claim Your Stake Now
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the final trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A deeper look at Abbott Laboratories’ situation reveals a potential disconnect between market sentiment and operational reality, and raises a critical question: Is the market’s pessimism justified, or has a meaningful value opportunity emerged for long-term investors? Separating the Signal From the NoiseAbbott's recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven primarily by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the issue and laid out a clear turnaround plan: pricing and promotion initiatives plus a pipeline of at least eight new product launches in 2026, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope: a macro rotation of capital. During periods of economic optimism, investors often shift money away from defensive sectors such as healthcare and into higher-beta areas like artificial intelligence (AI) and the energy sector in pursuit of faster returns. That trend has swept up many fundamentally sound healthcare companies, including Abbott, pressuring their stock prices for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott’s core remains exceptionally strong, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in Nutrition, and the company’s health is most evident in these high-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, powered by market-leading innovation across critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. This product line, which lets users track glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit pace, while Structural Heart delivered strong organic growth of 8.7%. That performance reflects a portfolio of best-in-class products, such as MitraClip and TriClip, plus a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also making a major strategic move to secure future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. The deal positions Abbott to compete in the rapidly expanding cancer diagnostics market, adding a new, high-growth vertical that should contribute materially to revenue for years to come. This bullish outlook is not just company optimism; it is shared by professional analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and signaling a belief that the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on building a reliable income stream, Abbott’s dividend is a standout feature. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current prices, Abbott yields about 2.5%, letting investors lock in a higher rate of income from a historically reliable payer. The dividend payout ratio is around 68% of earnings but represents only about 37% of cash flow. That indicates Abbott generates more than enough cash to cover its dividend payments and retains room to increase them in the future. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from its business reality. Temporary headwinds in one division and a broad market rotation have depressed the stock price, yet Abbott’s fundamental growth engines are accelerating. The Medical Devices division continues to deliver strong results, the dividend remains a bedrock of reliability, and powerful catalysts such as the Exact Sciences acquisition are on the horizon. For investors with a long-term horizon, the present valuation highlights a meaningful gap between market price and fundamental value—an opportunity worth serious consideration. |
